Geometrical Measures Obtained from Pretreatment Postcontrast T1 Weighted MRIs Predict Survival Benefits from Bevacizumab in Glioblastoma Patients

BACKGROUND: Antiangiogenic therapies for glioblastoma (GBM) such as bevacizumab (BVZ), have been unable to extend survival in large patient cohorts. However, a subset of patients having angiogenesis-dependent tumors might benefit from these therapies. Currently, there are no biomarkers allowing to d...

Descripción completa

Detalles Bibliográficos
Autores principales: Molina, David, Pérez-Beteta, Julián, Martínez-González, Alicia, Sepúlveda, Juan M., Peralta, Sergi, Gil-Gil, Miguel J., Reynes, Gaspar, Herrero, Ana, De Las Peñas, Ramón, Luque, Raquel, Capellades, Jaume, Balaña, Carmen, Pérez-García, Víctor M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4996463/
https://www.ncbi.nlm.nih.gov/pubmed/27557121
http://dx.doi.org/10.1371/journal.pone.0161484

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4996463/
https://www.ncbi.nlm.nih.gov/pubmed/27557121
http://dx.doi.org/10.1371/journal.pone.0161484

Ejemplares similares